Citations

Clear

80 citation(s) found for "Pignolo, RJ".

Incidence of Respiratory Syncytial Virus in Community-Dwelling Adults Aged 18–64 Years Over 2 Seasons, 2022–2024, in a North American Community
Bosch, Wendelyn , Speiser, Lisa , Wi, Chung‐Il , King, Katherine S. , Natoli, Traci L., Ihrke, Kathy, Spiten, Matthew J., Binnicker, Matthew J. , Yao, Joseph D. , Takahashi, Paul Y. , Pignolo, Robert J. , Foss, Randy , Pirçon, Jean‐Yves , Saeedi, Pouya , Oujaa, Mohamed, Juhn, Young J. , Speiser, Lisa J , Ihrke, Kathy D, Hidaka, Brandon , Foss, Randy , Juhn, Y J , King, Katherine , Takahashi, Paul , Wi, Chung-Ii , Hidaka, Brandon H.

Mayo Clinic

Open Forum Infectious Diseases | October 11, 2024 | Volume: 11 | Issue: 10 | Pages: No page available

10.1093/ofid/ofae597 | PMID 39474445 Get It

Abstract Background The incidence of respiratory syncytial virus (RSV)–acute respiratory infection (ARI) in community-dwelling adults after the Omicron variant of the COVID-19 pandemic is unknown. Our aim was to assess the incidence of RSV-ARI in adults aged 18 to 64 years over 2 consecutive RSV seasons (October–April 2022–2024) in 4 US states. Methods This community-based prospective cohort study comprised 7501 participants in Minnesota, Wisconsin, Florida, and Arizona. We calculated RSV-ARI and RSV–lower respiratory tract disease (LRTD) incidence and attack rates. We reported unadjusted incidence by age group, gender, race and ethnicity, Charlson Comorbidity Index, socioeconomic status, residential state, and rural/urban setting. Results Seasons 1 and 2 had 2250 and 2377 ARI episodes, respectively, with an RSV-ARI positivity rate of 5.5% for season 1 and 5.8% for season 2 among those tested. In season 1, the overall incidence of RSV-ARI was 27.71 (95% CI, 22.82–33.34) per 1000 person-years (1.49% attack rate). Almost half (49.0%) had RSV-LRTD, with an incidence of 13.53 (95% CI, 10.19–17.61) per 1000 person-years (0.73% attack rate). In season 2, the RSV-ARI and RSV-LRTD incidence rates were 26.39 (95% CI, 21.73–31.75) per 1000 person-years (1.51% attack rate) and 12.43 (95% CI, 9.31–16.26) per 1000 person-years (0.72% attack rate). RSV-ARI incidence peaked in November 2022 and December 2023. Conclusions Our observations suggest that RSV-ARI incidence and seasonal pattern are shifting to prepandemic RSV epidemiology.
Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial
Dahir, Kathryn , McGinniss, Jennifer, Sanchez, Robert J., Mellis, Scott , Rocco, Maja Di , Roux, Christian , Mukaddam, Mona Al , Mohammadi, Kusha , Srinivasan, Dushyanth , Trotter, Dinko González , Pignolo, Robert J. , Dahir, Kathryn M , Sanchez, Robert J , Trotter, Dinko Gonzalez , Keen, Richard , Economides, Aris N. , Orcel, Philippe , Tabarkiewicz, Jacek , Bachiller‐Corral, Javier , Cheung, Angela M. , Gu, Jing , Eekhoff, Elisabeth M. W. , Kaplan, Frederick S.

Mayo Clinic

Journal of Bone and Mineral Research | August 31, 2024 | Volume: 39 | Issue: 10 | Pages: 1486-1492

10.1093/jbmr/zjae140 | PMID 39216107 Get It

Abstract Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disorder, characterized by progressive heterotopic ossification (HO) and painful soft-tissue inflammatory flare-ups. This was a post hoc analysis from a phase 2 (NCT03188666) trial in which adults with FOP received intravenous anti-activin A antibody garetosmab 10 mg/kg or placebo every 4 wk over 28 wk (Period 1), followed by a 28-wk open-label treatment and extension (Periods 2 and 3). Here we describe flare-ups, their relationship to new HO lesions, and the impact of garetosmab on flare-ups. Volume of new HO lesions was measured by CT. Patient-reported flare-ups were defined by any 2 of the following: new onset of pain, swelling, joint stiffness, decrease in movement, or perceived presence of HO. Flare-ups were experienced by 71% (17/24) of placebo-treated patients, 59% (10/17) of whom developed a new HO lesion irrespective of flare-up location; 24% of flare-ups location-matched new HO lesions. Twenty-nine new HO lesions occurred in the placebo cohort by week 28, of which 12 (41%) occurred in the same location as new or ongoing flare-ups. A higher volume of newly formed heterotopic bone (week 28) occurred in placebo-treated patients who had experienced a prior flare-up vs those without (median [Q1:Q3] of 16.6 [12.0:31.1] vs 3.2 cm3). Garetosmab was previously shown to decrease patient-reported flare-up frequency in Period 1; here, garetosmab reduced the median (Q1:Q3) duration of patient-reported flares (15.0 [6.0:82.0] vs 48.0 [15.0:1.00] d) and the severity of flare-ups vs placebo. Frequency of corticosteroid use was numerically reduced in those treated with garetosmab (40.0%) vs placebo (58.3%). In this analysis, 71% of placebo-treated adults with FOP experienced flare-ups over 28 wk, which were associated with an increased volume of newly formed heterotopic bone. Garetosmab reduced the severity and duration of flare-ups, with effects sustained during the entire trial.
Bringing Geroscience into the Mainstream: From Education to Clinical Practice, What Will It Take?
Al‐Naggar, Iman M. , Justice, Jamie N. , Orr, Miranda E. , Kozikowski, Chester, Willik, Odette van der, Thatcher, Christine, Schmader, Kenneth E. , Pignolo, Robert J. , Newman, John C. , Justice, Jamie N , Newman, John C , Campellone, Kenneth G. , Espinoza, Sara , Kuchel, George A.

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | August 10, 2024 | Volume: 79 | Issue: 9 | Pages: No page available

10.1093/gerona/glae020 | PMID 39126344 Get It

A Pragmatic Approach to Introducing Translational Geroscience Into the Clinic: A Paradigm Based on the Incremental Progression of Aging-Related Clinical Research
Forman, Daniel E. , Pignolo, Robert J. , Forman, Daniel Edward

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | August 10, 2024 | Volume: 79 | Issue: 9 | Pages: No page available

10.1093/gerona/glae062 | PMID 39126296 Get It

Abstract Geroscience posits that molecular drivers underlie the aging process. Gerotherapeutics entail strategies to counter molecular drivers of aging to reduce the chronic diseases and geriatric syndromes they trigger. Although the concept of gerotherapeutics for prevention has generated much excitement, the implications of prescribing potentially harmful medications to older adults who are “healthy” have been associated with many delays. Concerns regarding safety and valid endpoints have contributed to holdups. In contrast, it has been relatively easier to implement trials of medications with gerotherapeutic properties as novel approaches to remedy disease. In these applications, the risks of the medications are easier to justify when therapeutic benefits are perceived as outweighing the harms of the disease. Likewise, metrics of effective disease treatments are often seen as more reliable and quantifiable than metrics of health prolongation. Overall, clarifying geroscience mechanisms in disease therapeutic applications provides key opportunities to advance translational geroscience, especially as preventive geroscience trials are often encumbered. In this review, gerotherapeutic benefits of canakinumab, cholchicine, and zoledronic acid as parts of disease management are considered. Longevity Clinics and other opportunities to advance translational geroscience as parts of contemporary care are also discussed.
Soft tissue aneurysmal bone cyst presenting as an enlarging neck mass: Case report and review of the head and neck literature
Chan, Stephen A. , Benson, John C. , Wittich, Michelle A. Neben, Chatzopoulos, Kyriakos , García, Joaquín J. , Geiersbach, Katherine B. , Gruber, Lucinda , Wermers, Robert A. , Pignolo, Robert J. , Rose, Peter S. , Abel, Kathryn M. Van , Neben Wittich, Michelle A, Van Abel, Kathryn M , Benson, John , Geiersbach, Katherine

Mayo Clinic

The Neuroradiology Journal | August 6, 2024 | Volume: 38 | Issue: 3 | Pages: 377-381

10.1177/19714009241269441 | PMID 39106298 Get It

Soft tissue aneurysmal bone cysts (STABCs) are rare neoplasms histopathologically identical to aneurysmal bone cysts. These benign lesions are characterized by thin, peripheral ossification and no skeletal continuity. STABC may be difficult to distinguish from myositis ossificans (MO) and malignant entities from imaging and fine needle aspiration, due to rarity and overlapping features. We present a case of a STABC occurring in the paraspinal cervical muscles. The imaging, histopathology, molecular analysis, and treatment are discussed. Four other published cases of STABC of the head and neck are reviewed.
Primary cilia mediate skeletogenic BMP and Hedgehog signaling in heterotopic ossification
He, Kai , Jiang, Heng , Li, Weijun , Toutounchi, Saman , Ma, Xiaoyu , Baehr, Wolfgang , Pignolo, Robert J. , Ling, Kun , Wang, Haitao , Hu, Jinghua , Ma, Xiaoyu , Zhou, Xuhui , Wang, Haitao , Hu, Jinghua , He, Kai , Huang, Yan , Wu, Jianfeng

Mayo Clinic

Science Translational Medicine | July 24, 2024 | Volume: 16 | Issue: 757 | Pages: No page available

10.1126/scitranslmed.abn3486 | PMID 39047114 Get It

Heterotopic ossification (HO), defined as the formation of extraskeletal bone in muscle and soft tissues, is a diverse pathological process caused by either genetic mutations or inciting trauma. Fibrodysplasia ossificans progressiva (FOP) is a genetic form of HO caused by mutations in the bone morphogenetic protein (BMP) type I receptor gene activin A receptor type 1 ( ACVR1 ). These mutations make ACVR1 hypersensitive to BMP and responsive to activin A. Hedgehog (Hh) signaling also contributes to HO development. However, the exact pathophysiology of how skeletogenic cells contribute to endochondral ossification in FOP remains unknown. Here, we showed that the wild-type or FOP-mutant ACVR1 localized in the cilia of stem cells from human exfoliated deciduous teeth with key FOP signaling components, including activin A receptor type 2A/2B, SMAD family member 1/5, and FK506-binding protein 12kD. Cilia suppression by deletion of intraflagellar transport 88 or ADP ribosylation factor like GTPase 3 effectively inhibited pathological BMP and Hh signaling, subdued aberrant chondro-osteogenic differentiation in primary mouse or human FOP cells, and diminished in vivo extraskeletal ossification in Acvr1 Q207D , Sox2-Cre ; Acvr1 R206H/+ FOP mice and in burn tenotomy–treated wild-type mice. Our results provide a rationale for early and localized suppression of cilia in affected tissues after injury as a therapeutic strategy against either genetic or acquired HO.
Osteochondroprogenitor cells and neutrophils expressing p21 and senescence markers modulate fracture repair
Saul, Dominik , Doolittle, Madison L. , Froemming, Mitchell N. , Kosinsky, Robyn Laura , Vos, Stephanie J. B. , Ruan, Ming, LeBrasseur, Nathan K. , Chandra, Abhishek , Pignolo, Robert J. , Rowsey, Jennifer L. , Kosinsky, Robyn L, Vos, Stephanie J, LeBrasseur, Nathan K , Kosinsky, Robyn Laura , Saul, Dominik , Chandra, Abhishek , Vos, Stephanie J., Passos, João F. , Farr, Joshua N. , Monroe, David G. , Khosla, Sundeep

Mayo Clinic

Journal of Clinical Investigation | May 16, 2024 | Volume: 134 | Issue: 12 | Pages: No page available

10.1172/jci179834 | PMID 38753433 Get It

Cells expressing features of senescence, including upregulation of p21 and p16, appear transiently following tissue injury, yet the properties of these cells or how they contrast with age-induced senescent cells remains unclear. Here, we used skeletal injury as a model and identified the rapid appearance following fracture of p21 + cells expressing senescence markers, mainly as osteochondroprogenitors (OCHs) and neutrophils. Targeted genetic clearance of p21 + cells suppressed senescence-associated signatures within the fracture callus and accelerated fracture healing. By contrast, p21 + cell clearance did not alter bone loss due to aging; conversely, p16 + cell clearance, known to alleviate skeletal aging, did not affect fracture healing. Following fracture, p21 + neutrophils were enriched in signaling pathways known to induce paracrine stromal senescence, while p21 + OCHs were highly enriched in senescence-associated secretory phenotype factors known to impair bone formation. Further analysis revealed an injury-specific stem cell–like OCH subset that was p21 + and highly inflammatory, with a similar inflammatory mesenchymal population (fibro-adipogenic progenitors) evident following muscle injury. Thus, intercommunicating senescent-like neutrophils and mesenchymal progenitor cells were key regulators of tissue repair in bone and potentially across tissues. Moreover, our findings established contextual roles of p21 + versus p16 + senescent/senescent-like cells that may be leveraged for therapeutic opportunities.
Cell Senescence in Heterotopic Ossification
Pignolo, Robert J. , Wang, Haitao , Wang, Haitao , Kaplan, Frederick S.

Mayo Clinic

Biomolecules | April 16, 2024 | Volume: 14 | Issue: 4 | Pages: 485

10.3390/biom14040485 | PMID 38672501 Get It

The formation of bone outside the normal skeleton, or heterotopic ossification (HO), occurs through genetic and acquired mechanisms. Fibrodysplasia ossificans progressiva (FOP), the most devastating genetic condition of HO, is due to mutations in the ACVR1/ALK2 gene and is relentlessly progressive. Acquired HO is mostly precipitated by injury or orthopedic surgical procedures but can also be associated with certain conditions related to aging. Cellular senescence is a hallmark of aging and thought to be a tumor-suppressive mechanism with characteristic features such as irreversible growth arrest, apoptosis resistance, and an inflammatory senescence-associated secretory phenotype (SASP). Here, we review possible roles for cellular senescence in HO and how targeting senescent cells may provide new therapeutic approaches to both FOP and acquired forms of HO.